Suppr超能文献

回顾性比较行超声心动图检查与不行超声心动图检查的危重症住院患者的死亡率。

A retrospective comparison of mortality in critically ill hospitalized patients undergoing echocardiography with and without an ultrasound contrast agent.

机构信息

ICON Clinical Research, San Francisco, California, USA.

出版信息

JACC Cardiovasc Imaging. 2010 Jun;3(6):578-85. doi: 10.1016/j.jcmg.2010.04.006.

Abstract

OBJECTIVES

To compare acute mortality in critically ill hospitalized patients undergoing echocardiography with and without an ultrasound contrast agent (UCA).

BACKGROUND

Because of serious cardiopulmonary reactions reported immediately after administration of perflutren-containing UCAs, the FDA required a black box safety warning for this class of agents, including perflutren protein-type A microspheres injectable suspension.

METHODS

This study used the largest hospital service-level database in the U.S. All adult patients undergoing in-patient echocardiography between January 2003 and October 2005 were identified (n = 2,588,722, of which 22,499 received perflutren protein-type A microspheres injectable suspension). Of the 22,499 contrast echocardiography patients, 2,900 had diagnoses meeting criteria for critical illness (heart failure, acute myocardial infarction, arrhythmia, respiratory failure, pulmonary embolism, emphysema, and pulmonary hypertension). To control for the differences between the contrast and noncontrast patients, we used propensity score matching. Variables used in the construction of the propensity score included comorbidities, demographic factors, hospital-specific factors, level of care, and mechanical ventilation status. Patients receiving contrast echocardiography were matched to 4 control patients who received noncontrast echocardiography. Conditional logistic regression was used to estimate mortality effects.

RESULTS

There were 167 deaths in the study among critically ill patients, 38 of 2,900 from the contrast group and 129 of 11,600 from the control group. The contrast agent was not associated with an increase in same-day mortality (odds ratio: 1.18; 95% confidence interval: 0.82 to 1.71; p = 0.37). Before matching, contrast patients showed greater morbidity than noncontrast patients (Deyo-Charlson comorbidity score 2.45 vs. 2.25, p < 0.0001). After propensity score matching, these differences were significantly reduced, showing that both groups were well balanced.

CONCLUSIONS

There is no increase in mortality in critically ill patients undergoing echocardiography with the UCA compared with case-matched control patients.

摘要

目的

比较接受超声心动图检查的危重症住院患者使用和不使用超声对比剂(UCA)的急性死亡率。

背景

由于使用含有全氟丙烷的 UCA 后立即报告了严重的心肺反应,FDA 要求对这类药物(包括全氟丙烷蛋白 A 微球注射悬浮液)发出黑框安全警告。

方法

本研究使用了美国最大的医院服务水平数据库。在 2003 年 1 月至 2005 年 10 月期间,确定了所有接受住院超声心动图检查的成年患者(n=2588722,其中 22499 例接受了全氟丙烷蛋白 A 微球注射悬浮液)。在 22499 例对比超声心动图患者中,有 2900 例患者的诊断符合危重症标准(心力衰竭、急性心肌梗死、心律失常、呼吸衰竭、肺栓塞、肺气肿和肺动脉高压)。为了控制对比组和非对比组患者之间的差异,我们使用了倾向评分匹配。在构建倾向评分时使用的变量包括合并症、人口统计学因素、医院特定因素、护理水平和机械通气状态。接受对比超声心动图检查的患者与接受非对比超声心动图检查的 4 名对照患者进行匹配。使用条件逻辑回归估计死亡率的影响。

结果

在研究中,有 167 例危重症患者死亡,其中 2900 例患者中有 38 例来自对比组,11600 例患者中有 129 例来自对照组。对比剂并未增加当天的死亡率(比值比:1.18;95%置信区间:0.82 至 1.71;p=0.37)。在匹配之前,对比组患者的发病率高于非对比组患者(Deyo-Charlson 合并症评分 2.45 与 2.25,p<0.0001)。在倾向评分匹配后,这些差异显著降低,表明两组患者的情况得到了很好的平衡。

结论

与匹配对照患者相比,接受超声心动图检查的危重症患者使用 UCA 并未增加死亡率。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验